DSGN — Design Therapeutics, Inc.
Is DSGN overbought or oversold? Here is the current MarketMoodz read.
Design Therapeutics, Inc. (DSGN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $9.84. The rating moved from Neutral to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$9.84
- Last changeMoved from Neutral to Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Design Therapeutics is a small-cap biotech where valuation is mainly driven by pipeline and clinical milestones; limited public filing and sentiment data raise uncertainty around financial runway and execution. Near-term performance will hinge on clinical updates, partnership activity, and any funding actions. Market conditions are broadly consolidative with selective support for growth stocks, offering episodic windows for upside if positive news emerges but also leaving the stock exposed to typical small-cap biotech volatility and dilution risk.
Key factors
- Limited public financial disclosure and no recent EDGAR filing comparison available increases uncertainty around cash runway and revenue visibility
- Small-cap biotechnology profile with value driven primarily by pipeline progress and clinical readouts rather than near-term commercial revenue
- Market environment showing consolidation and selective support for growth names; this can provide episodic support for biotech risk assets but limits sustained momentum
- Potential catalysts include upcoming clinical milestones, partnership or licensing announcements, and any positive trial data or regulatory feedback
- Low social sentiment / research coverage available currently, which may limit retail-driven price moves but also reduces easily observable sentiment risk
Risks
- Clinical or regulatory setbacks for lead programs that could materially reduce valuation
- Unknown cash runway and potential for dilution via equity raises if operating burn continues without partnering or revenue
- Low liquidity and higher share price volatility typical of small-cap biotech names
- Competitive risk from larger pharma entrants and consolidation in specialty franchises that could limit partnership terms or acquisition interest
- Reimbursement and payer uncertainty for novel therapies, and potential downstream impacts from evolving regulatory focus in healthcare programs
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for DSGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.